 Casey Greene
Concepts (416)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Computational Biology | 32 | 2025 | 661 | 5.600 |
Why?
| | Gene Expression Profiling | 23 | 2025 | 1764 | 4.010 |
Why?
| | Software | 17 | 2025 | 676 | 2.920 |
Why?
| | Single-Cell Analysis | 8 | 2025 | 338 | 2.820 |
Why?
| | Machine Learning | 18 | 2024 | 553 | 2.790 |
Why?
| | Genomics | 18 | 2025 | 814 | 2.630 |
Why?
| | Transcriptome | 20 | 2024 | 1003 | 2.490 |
Why?
| | Algorithms | 18 | 2025 | 1763 | 2.210 |
Why?
| | Gene Regulatory Networks | 10 | 2024 | 313 | 2.200 |
Why?
| | Information Dissemination | 6 | 2020 | 224 | 2.160 |
Why?
| | Epistasis, Genetic | 6 | 2023 | 68 | 1.670 |
Why?
| | Sequence Analysis, RNA | 8 | 2025 | 450 | 1.600 |
Why?
| | Data Mining | 5 | 2018 | 118 | 1.560 |
Why?
| | Pseudomonas aeruginosa | 7 | 2024 | 358 | 1.560 |
Why?
| | Biomedical Research | 5 | 2025 | 703 | 1.550 |
Why?
| | Neoplasms | 12 | 2022 | 2741 | 1.500 |
Why?
| | Ovarian Neoplasms | 9 | 2025 | 580 | 1.490 |
Why?
| | Viral Vaccines | 2 | 2023 | 107 | 1.450 |
Why?
| | Rare Diseases | 2 | 2023 | 111 | 1.330 |
Why?
| | Databases, Genetic | 13 | 2022 | 242 | 1.300 |
Why?
| | Gene Expression | 4 | 2023 | 1491 | 1.120 |
Why?
| | Research Personnel | 2 | 2020 | 183 | 1.070 |
Why?
| | Genome-Wide Association Study | 10 | 2021 | 1402 | 1.050 |
Why?
| | Humans | 104 | 2025 | 141187 | 0.920 |
Why?
| | Natural Language Processing | 2 | 2024 | 99 | 0.920 |
Why?
| | Peer Review, Research | 2 | 2022 | 42 | 0.900 |
Why?
| | Nonlinear Dynamics | 2 | 2023 | 92 | 0.890 |
Why?
| | Artificial Intelligence | 4 | 2024 | 334 | 0.870 |
Why?
| | Journalism | 1 | 2024 | 7 | 0.870 |
Why?
| | Direct-To-Consumer Screening and Testing | 1 | 2024 | 2 | 0.860 |
Why?
| | Breeding | 1 | 2024 | 65 | 0.840 |
Why?
| | Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2023 | 33 | 0.810 |
Why?
| | Cystadenocarcinoma, Serous | 4 | 2025 | 83 | 0.760 |
Why?
| | User-Computer Interface | 4 | 2023 | 164 | 0.740 |
Why?
| | Societies, Scientific | 1 | 2021 | 51 | 0.700 |
Why?
| | Genetic Testing | 1 | 2024 | 460 | 0.680 |
Why?
| | Neurofibromin 1 | 2 | 2019 | 25 | 0.680 |
Why?
| | Metadata | 1 | 2020 | 15 | 0.670 |
Why?
| | Data Compression | 1 | 2020 | 5 | 0.660 |
Why?
| | Guidelines as Topic | 1 | 2022 | 273 | 0.630 |
Why?
| | Computer Security | 1 | 2019 | 24 | 0.610 |
Why?
| | Computer Simulation | 7 | 2025 | 1015 | 0.610 |
Why?
| | Genetic Association Studies | 3 | 2016 | 372 | 0.610 |
Why?
| | Precision Medicine | 5 | 2024 | 434 | 0.590 |
Why?
| | Confidentiality | 1 | 2019 | 73 | 0.590 |
Why?
| | Language | 1 | 2022 | 308 | 0.590 |
Why?
| | High-Throughput Nucleotide Sequencing | 4 | 2021 | 546 | 0.580 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 178 | 0.580 |
Why?
| | Scholarly Communication | 1 | 2018 | 2 | 0.570 |
Why?
| | Databases, Bibliographic | 1 | 2018 | 32 | 0.560 |
Why?
| | ras Proteins | 2 | 2019 | 148 | 0.560 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2025 | 646 | 0.560 |
Why?
| | Probability | 3 | 2024 | 309 | 0.540 |
Why?
| | Access to Information | 1 | 2018 | 49 | 0.540 |
Why?
| | Biomedical Technology | 1 | 2018 | 50 | 0.540 |
Why?
| | Disease | 3 | 2018 | 102 | 0.530 |
Why?
| | Glioblastoma | 2 | 2019 | 347 | 0.520 |
Why?
| | Gene Silencing | 2 | 2018 | 196 | 0.520 |
Why?
| | alpha-Synuclein | 1 | 2017 | 43 | 0.510 |
Why?
| | Models, Biological | 3 | 2020 | 1828 | 0.500 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2016 | 136 | 0.500 |
Why?
| | Parasites | 1 | 2017 | 49 | 0.500 |
Why?
| | Genome, Human | 6 | 2018 | 420 | 0.490 |
Why?
| | Models, Genetic | 5 | 2019 | 591 | 0.490 |
Why?
| | Systems Biology | 3 | 2018 | 70 | 0.480 |
Why?
| | Gene Ontology | 5 | 2020 | 53 | 0.480 |
Why?
| | MicroRNAs | 1 | 2022 | 689 | 0.470 |
Why?
| | Workflow | 1 | 2017 | 171 | 0.470 |
Why?
| | Quantitative Trait, Heritable | 1 | 2016 | 124 | 0.460 |
Why?
| | Research | 1 | 2018 | 455 | 0.460 |
Why?
| | Protein Interaction Maps | 1 | 2015 | 49 | 0.460 |
Why?
| | Unsupervised Machine Learning | 4 | 2024 | 23 | 0.450 |
Why?
| | Neurodegenerative Diseases | 1 | 2017 | 140 | 0.450 |
Why?
| | Bacterial Proteins | 2 | 2020 | 911 | 0.440 |
Why?
| | Tumor Microenvironment | 4 | 2023 | 692 | 0.420 |
Why?
| | Internet | 5 | 2023 | 690 | 0.420 |
Why?
| | Authorship | 2 | 2024 | 54 | 0.420 |
Why?
| | Models, Theoretical | 1 | 2017 | 585 | 0.410 |
Why?
| | Bayes Theorem | 5 | 2018 | 417 | 0.400 |
Why?
| | RNA, Untranslated | 1 | 2014 | 124 | 0.380 |
Why?
| | Cluster Analysis | 3 | 2024 | 521 | 0.360 |
Why?
| | Drosophila melanogaster | 5 | 2019 | 237 | 0.350 |
Why?
| | Microbiota | 2 | 2017 | 767 | 0.350 |
Why?
| | Pandemics | 5 | 2023 | 1653 | 0.350 |
Why?
| | Signal Transduction | 8 | 2020 | 5144 | 0.340 |
Why?
| | Bibliometrics | 2 | 2024 | 65 | 0.340 |
Why?
| | Writing | 2 | 2024 | 101 | 0.330 |
Why?
| | Publishing | 2 | 2024 | 145 | 0.330 |
Why?
| | Embryonic Development | 3 | 2020 | 118 | 0.320 |
Why?
| | Databases, Factual | 2 | 2018 | 1444 | 0.310 |
Why?
| | Molecular Sequence Annotation | 5 | 2023 | 95 | 0.310 |
Why?
| | Terminology as Topic | 3 | 2022 | 244 | 0.300 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2010 | 98 | 0.290 |
Why?
| | Female | 24 | 2025 | 75515 | 0.290 |
Why?
| | Scleroderma, Systemic | 3 | 2017 | 122 | 0.290 |
Why?
| | Supervised Machine Learning | 2 | 2020 | 20 | 0.290 |
Why?
| | Genome | 2 | 2019 | 302 | 0.290 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2021 | 2132 | 0.270 |
Why?
| | Betacoronavirus | 2 | 2020 | 276 | 0.270 |
Why?
| | Animals | 19 | 2025 | 37657 | 0.260 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 898 | 0.260 |
Why?
| | Drosophila Proteins | 2 | 2019 | 204 | 0.250 |
Why?
| | Homologous Recombination | 1 | 2025 | 29 | 0.240 |
Why?
| | Proteomics | 4 | 2021 | 1134 | 0.240 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 374 | 0.230 |
Why?
| | Coronavirus Infections | 2 | 2020 | 371 | 0.230 |
Why?
| | Data Interpretation, Statistical | 2 | 2018 | 376 | 0.230 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2021 | 277 | 0.230 |
Why?
| | Publications | 2 | 2022 | 51 | 0.220 |
Why?
| | Reproducibility of Results | 6 | 2021 | 3348 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 5 | 2021 | 2363 | 0.210 |
Why?
| | Mice | 12 | 2025 | 18048 | 0.200 |
Why?
| | Sexism | 1 | 2024 | 68 | 0.200 |
Why?
| | Science | 1 | 2024 | 55 | 0.200 |
Why?
| | Cystic Fibrosis | 2 | 2024 | 1126 | 0.200 |
Why?
| | Breast Neoplasms | 2 | 2015 | 2250 | 0.200 |
Why?
| | Cell Line, Tumor | 4 | 2019 | 3469 | 0.200 |
Why?
| | Causality | 1 | 2023 | 130 | 0.200 |
Why?
| | Vaccines, Subunit | 1 | 2023 | 50 | 0.190 |
Why?
| | Pedigree | 1 | 2024 | 511 | 0.190 |
Why?
| | Dogs | 1 | 2024 | 427 | 0.190 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2019 | 256 | 0.190 |
Why?
| | Sample Size | 1 | 2022 | 128 | 0.190 |
Why?
| | Mushroom Bodies | 2 | 2019 | 4 | 0.190 |
Why?
| | Hedgehog Proteins | 2 | 2021 | 200 | 0.180 |
Why?
| | Male | 16 | 2025 | 69783 | 0.180 |
Why?
| | Pseudomonas Infections | 1 | 2024 | 230 | 0.180 |
Why?
| | Periodicals as Topic | 1 | 2024 | 217 | 0.180 |
Why?
| | Quality Control | 1 | 2021 | 171 | 0.170 |
Why?
| | High-Throughput Screening Assays | 2 | 2014 | 157 | 0.170 |
Why?
| | ADAM10 Protein | 1 | 2021 | 29 | 0.170 |
Why?
| | Neoplasm Grading | 4 | 2025 | 316 | 0.170 |
Why?
| | Fibrosis | 2 | 2021 | 541 | 0.170 |
Why?
| | Bone Development | 1 | 2021 | 54 | 0.170 |
Why?
| | Gamma Rays | 1 | 2021 | 57 | 0.170 |
Why?
| | Cooperative Behavior | 2 | 2021 | 462 | 0.170 |
Why?
| | Linear Models | 1 | 2023 | 857 | 0.170 |
Why?
| | Electronic Health Records | 3 | 2018 | 1122 | 0.160 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 79 | 0.160 |
Why?
| | Medical Informatics | 1 | 2021 | 101 | 0.160 |
Why?
| | Cystadenoma, Serous | 1 | 2020 | 18 | 0.160 |
Why?
| | Organ Specificity | 3 | 2017 | 312 | 0.160 |
Why?
| | Pancreatic Neoplasms | 2 | 2021 | 882 | 0.160 |
Why?
| | Mutation | 5 | 2025 | 4013 | 0.160 |
Why?
| | Hemerythrin | 1 | 2020 | 1 | 0.160 |
Why?
| | Privacy | 1 | 2020 | 42 | 0.160 |
Why?
| | Alzheimer Disease | 2 | 2017 | 583 | 0.160 |
Why?
| | Bone Diseases | 1 | 2021 | 66 | 0.160 |
Why?
| | Histone Code | 1 | 2020 | 33 | 0.160 |
Why?
| | Systems Integration | 2 | 2017 | 38 | 0.160 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 96 | 0.160 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2020 | 1431 | 0.160 |
Why?
| | Radiation Injuries | 1 | 2021 | 149 | 0.150 |
Why?
| | Neurofibromatosis 1 | 1 | 2020 | 56 | 0.150 |
Why?
| | Phenotype | 4 | 2021 | 3166 | 0.150 |
Why?
| | Genetic Fitness | 1 | 2020 | 57 | 0.150 |
Why?
| | Base Sequence | 1 | 2022 | 2180 | 0.150 |
Why?
| | Cell Hypoxia | 1 | 2020 | 231 | 0.150 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 213 | 0.150 |
Why?
| | Exons | 1 | 2020 | 353 | 0.150 |
Why?
| | Biofilms | 2 | 2019 | 271 | 0.150 |
Why?
| | Gene Expression Regulation | 3 | 2018 | 2599 | 0.150 |
Why?
| | Computer Communication Networks | 1 | 2018 | 33 | 0.150 |
Why?
| | Cerebellar Neoplasms | 1 | 2021 | 179 | 0.150 |
Why?
| | Radiosurgery | 1 | 2022 | 392 | 0.150 |
Why?
| | DNA Repair | 2 | 2011 | 234 | 0.140 |
Why?
| | Medulloblastoma | 1 | 2021 | 218 | 0.140 |
Why?
| | Hypertension | 2 | 2019 | 1252 | 0.140 |
Why?
| | Pseudomonas fluorescens | 1 | 2018 | 2 | 0.140 |
Why?
| | Proteins | 2 | 2016 | 1010 | 0.140 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2019 | 528 | 0.140 |
Why?
| | Sex Factors | 1 | 2024 | 2058 | 0.140 |
Why?
| | Alternative Splicing | 1 | 2020 | 232 | 0.140 |
Why?
| | Biomarkers, Tumor | 1 | 2025 | 1251 | 0.140 |
Why?
| | Recombinational DNA Repair | 1 | 2018 | 16 | 0.140 |
Why?
| | Atlases as Topic | 1 | 2018 | 11 | 0.140 |
Why?
| | Cyclic GMP | 1 | 2018 | 91 | 0.140 |
Why?
| | Bone and Bones | 1 | 2021 | 317 | 0.140 |
Why?
| | Down Syndrome | 1 | 2025 | 506 | 0.140 |
Why?
| | Immunity, Cellular | 1 | 2019 | 269 | 0.140 |
Why?
| | Glomerulonephritis | 1 | 2018 | 47 | 0.140 |
Why?
| | Pennsylvania | 1 | 2018 | 133 | 0.140 |
Why?
| | Papillomavirus Infections | 1 | 2022 | 380 | 0.140 |
Why?
| | Public Sector | 1 | 2017 | 18 | 0.140 |
Why?
| | False Positive Reactions | 1 | 2018 | 125 | 0.140 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 553 | 0.130 |
Why?
| | Trans-Activators | 1 | 2020 | 388 | 0.130 |
Why?
| | Starvation | 1 | 2017 | 23 | 0.130 |
Why?
| | Central Nervous System Neoplasms | 1 | 2019 | 169 | 0.130 |
Why?
| | Phosphoproteins | 1 | 2019 | 338 | 0.130 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 432 | 0.130 |
Why?
| | Drug Design | 1 | 2018 | 168 | 0.130 |
Why?
| | Metabolic Networks and Pathways | 1 | 2018 | 184 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 725 | 0.130 |
Why?
| | Information Storage and Retrieval | 1 | 2017 | 120 | 0.120 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 286 | 0.120 |
Why?
| | Multiple Myeloma | 1 | 2019 | 282 | 0.120 |
Why?
| | Data Collection | 1 | 2019 | 661 | 0.120 |
Why?
| | Amygdala | 1 | 2017 | 192 | 0.120 |
Why?
| | Genome, Microbial | 1 | 2016 | 7 | 0.120 |
Why?
| | Body Mass Index | 1 | 2025 | 2382 | 0.120 |
Why?
| | Microbial Consortia | 1 | 2016 | 20 | 0.120 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2015 | 14 | 0.120 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2018 | 320 | 0.120 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2018 | 761 | 0.120 |
Why?
| | Memory | 1 | 2017 | 262 | 0.120 |
Why?
| | Drug Repositioning | 1 | 2015 | 39 | 0.120 |
Why?
| | Blood Pressure | 2 | 2019 | 1748 | 0.120 |
Why?
| | Phylogeny | 1 | 2020 | 1018 | 0.110 |
Why?
| | Toxicology | 1 | 2015 | 44 | 0.110 |
Why?
| | Structure-Activity Relationship | 1 | 2016 | 579 | 0.110 |
Why?
| | Antihypertensive Agents | 1 | 2019 | 508 | 0.110 |
Why?
| | Social Behavior | 1 | 2017 | 293 | 0.110 |
Why?
| | Search Engine | 1 | 2015 | 12 | 0.110 |
Why?
| | Research Design | 1 | 2021 | 1143 | 0.110 |
Why?
| | Knowledge Bases | 1 | 2015 | 27 | 0.110 |
Why?
| | RNA | 4 | 2024 | 930 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2021 | 1154 | 0.110 |
Why?
| | Pharmacogenetics | 1 | 2015 | 167 | 0.110 |
Why?
| | Metabolome | 1 | 2017 | 366 | 0.110 |
Why?
| | Decision Support Techniques | 1 | 2018 | 431 | 0.110 |
Why?
| | Prognosis | 3 | 2021 | 4073 | 0.110 |
Why?
| | Genes | 3 | 2013 | 229 | 0.110 |
Why?
| | Hospital Mortality | 1 | 2018 | 924 | 0.100 |
Why?
| | Biological Phenomena | 1 | 2013 | 4 | 0.100 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2015 | 259 | 0.100 |
Why?
| | Circadian Rhythm | 1 | 2017 | 508 | 0.100 |
Why?
| | Proteome | 1 | 2017 | 483 | 0.100 |
Why?
| | Macrophages | 1 | 2021 | 1561 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1556 | 0.100 |
Why?
| | Podocytes | 1 | 2013 | 68 | 0.100 |
Why?
| | Sequence Analysis, DNA | 3 | 2025 | 824 | 0.100 |
Why?
| | Length of Stay | 1 | 2018 | 1254 | 0.090 |
Why?
| | Intensive Care Units | 1 | 2018 | 868 | 0.090 |
Why?
| | Adult | 8 | 2025 | 39177 | 0.090 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 1973 | 0.090 |
Why?
| | Receptors, Estrogen | 1 | 2015 | 412 | 0.090 |
Why?
| | Brain | 1 | 2024 | 2858 | 0.090 |
Why?
| | Middle Aged | 10 | 2025 | 34434 | 0.090 |
Why?
| | Polymorphism, Genetic | 2 | 2017 | 625 | 0.090 |
Why?
| | Cell Lineage | 1 | 2013 | 350 | 0.090 |
Why?
| | Survival Analysis | 1 | 2015 | 1319 | 0.090 |
Why?
| | Obesity | 1 | 2025 | 3004 | 0.090 |
Why?
| | Cell Line | 2 | 2017 | 2885 | 0.090 |
Why?
| | Aged | 8 | 2025 | 24574 | 0.090 |
Why?
| | Pediatrics | 1 | 2019 | 1094 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2018 | 961 | 0.080 |
Why?
| | Bias | 1 | 2012 | 229 | 0.080 |
Why?
| | Decision Making | 1 | 2018 | 961 | 0.080 |
Why?
| | Knowledge | 1 | 2010 | 59 | 0.080 |
Why?
| | Microglia | 2 | 2024 | 255 | 0.080 |
Why?
| | Multifactor Dimensionality Reduction | 1 | 2010 | 2 | 0.080 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1304 | 0.080 |
Why?
| | Models, Statistical | 3 | 2020 | 671 | 0.080 |
Why?
| | Memory, Long-Term | 2 | 2019 | 12 | 0.080 |
Why?
| | Transcription Factors | 1 | 2017 | 1703 | 0.080 |
Why?
| | Kidney Diseases | 1 | 2013 | 406 | 0.080 |
Why?
| | Rats | 3 | 2013 | 5629 | 0.070 |
Why?
| | Parkinson Disease | 1 | 2015 | 569 | 0.070 |
Why?
| | Geography | 1 | 2009 | 201 | 0.070 |
Why?
| | Biopsy | 3 | 2018 | 1081 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1396 | 0.070 |
Why?
| | Child | 4 | 2021 | 22308 | 0.070 |
Why?
| | Gene Frequency | 1 | 2009 | 494 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 5929 | 0.070 |
Why?
| | Cells, Cultured | 1 | 2015 | 4208 | 0.070 |
Why?
| | Multifactorial Inheritance | 1 | 2008 | 178 | 0.060 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2013 | 623 | 0.060 |
Why?
| | United States | 2 | 2021 | 15220 | 0.060 |
Why?
| | Terminal Repeat Sequences | 1 | 2006 | 18 | 0.060 |
Why?
| | Alleles | 1 | 2009 | 891 | 0.060 |
Why?
| | Cytokines | 2 | 2018 | 2098 | 0.060 |
Why?
| | Retroelements | 1 | 2006 | 49 | 0.060 |
Why?
| | Bone Density | 2 | 2021 | 494 | 0.060 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2025 | 40 | 0.060 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2025 | 42 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2009 | 3588 | 0.050 |
Why?
| | Treatment Outcome | 1 | 2019 | 11120 | 0.050 |
Why?
| | Pilot Projects | 2 | 2022 | 1820 | 0.050 |
Why?
| | Europe | 1 | 2025 | 410 | 0.050 |
Why?
| | Culture Media | 1 | 2024 | 163 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 99 | 0.050 |
Why?
| | Microarray Analysis | 1 | 2023 | 116 | 0.050 |
Why?
| | Metals | 1 | 2024 | 140 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2025 | 557 | 0.050 |
Why?
| | Astrocytes | 1 | 2024 | 217 | 0.050 |
Why?
| | Smoking | 1 | 2010 | 1601 | 0.050 |
Why?
| | Sputum | 1 | 2024 | 309 | 0.050 |
Why?
| | Budgets | 1 | 2021 | 14 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 5887 | 0.040 |
Why?
| | Interdisciplinary Research | 1 | 2021 | 26 | 0.040 |
Why?
| | Gene Library | 1 | 2021 | 120 | 0.040 |
Why?
| | Self Report | 1 | 2025 | 856 | 0.040 |
Why?
| | Ephrin-B2 | 1 | 2021 | 45 | 0.040 |
Why?
| | Neurofibroma | 1 | 2020 | 4 | 0.040 |
Why?
| | Nerve Sheath Neoplasms | 1 | 2020 | 12 | 0.040 |
Why?
| | Neurofibroma, Plexiform | 1 | 2020 | 12 | 0.040 |
Why?
| | Genetic Markers | 1 | 2021 | 343 | 0.040 |
Why?
| | Osteoblasts | 1 | 2021 | 134 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2021 | 211 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2020 | 92 | 0.040 |
Why?
| | Antigens, CD20 | 1 | 2019 | 35 | 0.040 |
Why?
| | Gene Editing | 1 | 2021 | 86 | 0.040 |
Why?
| | Data Accuracy | 1 | 2020 | 65 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2022 | 419 | 0.040 |
Why?
| | Candida albicans | 1 | 2019 | 57 | 0.040 |
Why?
| | Chromosome Mapping | 1 | 2021 | 504 | 0.040 |
Why?
| | Peripheral Nerves | 1 | 2020 | 71 | 0.040 |
Why?
| | Manuscripts, Medical as Topic | 1 | 2019 | 5 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2020 | 132 | 0.040 |
Why?
| | Genome, Fungal | 1 | 2019 | 40 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2025 | 7856 | 0.040 |
Why?
| | Young Adult | 3 | 2021 | 13673 | 0.040 |
Why?
| | Reward | 1 | 2021 | 256 | 0.040 |
Why?
| | Osteosarcoma | 1 | 2019 | 73 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 959 | 0.040 |
Why?
| | Osteogenesis | 1 | 2021 | 199 | 0.040 |
Why?
| | Rhabdomyosarcoma | 1 | 2019 | 74 | 0.040 |
Why?
| | Locomotion | 1 | 2019 | 106 | 0.040 |
Why?
| | Mentoring | 1 | 2021 | 151 | 0.040 |
Why?
| | Quantitative Trait Loci | 1 | 2021 | 364 | 0.040 |
Why?
| | Wilms Tumor | 1 | 2019 | 87 | 0.040 |
Why?
| | Genome, Bacterial | 1 | 2019 | 149 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2019 | 330 | 0.040 |
Why?
| | Neuroblastoma | 1 | 2019 | 163 | 0.040 |
Why?
| | Genes, Neoplasm | 1 | 2018 | 22 | 0.040 |
Why?
| | Sarcoma, Ewing | 1 | 2019 | 100 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 208 | 0.040 |
Why?
| | Two-Hybrid System Techniques | 1 | 2018 | 57 | 0.040 |
Why?
| | Pentose Phosphate Pathway | 1 | 2018 | 53 | 0.040 |
Why?
| | Loss of Heterozygosity | 1 | 2018 | 51 | 0.040 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2018 | 23 | 0.040 |
Why?
| | Bacteria | 1 | 2025 | 881 | 0.030 |
Why?
| | Nephrotic Syndrome | 1 | 2018 | 39 | 0.030 |
Why?
| | Monocytes | 1 | 2021 | 579 | 0.030 |
Why?
| | Acid Phosphatase | 1 | 2017 | 20 | 0.030 |
Why?
| | Mobile Applications | 1 | 2020 | 185 | 0.030 |
Why?
| | MAP Kinase Signaling System | 1 | 2019 | 325 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2020 | 464 | 0.030 |
Why?
| | Kidney Glomerulus | 1 | 2018 | 121 | 0.030 |
Why?
| | Kidney Tubules | 1 | 2018 | 116 | 0.030 |
Why?
| | Mouth | 1 | 2017 | 88 | 0.030 |
Why?
| | Isoenzymes | 1 | 2018 | 302 | 0.030 |
Why?
| | Patient Care Planning | 1 | 2018 | 155 | 0.030 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2017 | 92 | 0.030 |
Why?
| | GTPase-Activating Proteins | 1 | 2017 | 85 | 0.030 |
Why?
| | Wnt Proteins | 1 | 2018 | 136 | 0.030 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2017 | 109 | 0.030 |
Why?
| | RNA-Binding Proteins | 1 | 2021 | 440 | 0.030 |
Why?
| | Chromatin | 1 | 2021 | 529 | 0.030 |
Why?
| | Motivation | 1 | 2021 | 602 | 0.030 |
Why?
| | Databases, Protein | 1 | 2016 | 87 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 1110 | 0.030 |
Why?
| | Cell Movement | 1 | 2021 | 990 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 1970 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2021 | 1242 | 0.030 |
Why?
| | Saliva | 1 | 2017 | 245 | 0.030 |
Why?
| | Genetic Loci | 1 | 2017 | 277 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2018 | 368 | 0.030 |
Why?
| | Biopsy, Fine-Needle | 1 | 2016 | 70 | 0.030 |
Why?
| | Proof of Concept Study | 1 | 2016 | 85 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2018 | 234 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2021 | 712 | 0.030 |
Why?
| | Blood Proteins | 1 | 2017 | 250 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 739 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2018 | 325 | 0.030 |
Why?
| | Hydrocortisone | 1 | 2017 | 316 | 0.030 |
Why?
| | DNA Damage | 1 | 2018 | 427 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2018 | 497 | 0.030 |
Why?
| | Health Status | 1 | 2020 | 823 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 2086 | 0.030 |
Why?
| | Risk Factors | 1 | 2009 | 10438 | 0.030 |
Why?
| | Esophagus | 1 | 2017 | 257 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2021 | 918 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1052 | 0.030 |
Why?
| | Oxygen | 1 | 2020 | 993 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1487 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2016 | 600 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2017 | 573 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2019 | 874 | 0.030 |
Why?
| | Heart Rate | 1 | 2017 | 821 | 0.030 |
Why?
| | Aging | 1 | 2024 | 1892 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 914 | 0.030 |
Why?
| | Colorado | 1 | 2024 | 4610 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 674 | 0.030 |
Why?
| | Regression Analysis | 1 | 2015 | 1020 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2021 | 2504 | 0.020 |
Why?
| | Support Vector Machine | 1 | 2013 | 38 | 0.020 |
Why?
| | Organogenesis | 1 | 2013 | 61 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2902 | 0.020 |
Why?
| | Embryo, Nonmammalian | 1 | 2013 | 169 | 0.020 |
Why?
| | Nanotechnology | 1 | 2013 | 124 | 0.020 |
Why?
| | Computer Graphics | 1 | 2012 | 42 | 0.020 |
Why?
| | Risk | 1 | 2015 | 904 | 0.020 |
Why?
| | Skin | 1 | 2017 | 765 | 0.020 |
Why?
| | Apoptosis | 1 | 2021 | 2574 | 0.020 |
Why?
| | Adolescent | 2 | 2021 | 22007 | 0.020 |
Why?
| | Drug Interactions | 1 | 2013 | 406 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2015 | 555 | 0.020 |
Why?
| | Genetic Variation | 1 | 2015 | 1000 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2018 | 2828 | 0.020 |
Why?
| | Zebrafish Proteins | 1 | 2012 | 287 | 0.020 |
Why?
| | Caenorhabditis elegans | 1 | 2013 | 331 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5636 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4404 | 0.020 |
Why?
| | Repressor Proteins | 1 | 2012 | 425 | 0.020 |
Why?
| | Zebrafish | 1 | 2013 | 500 | 0.020 |
Why?
| | Curriculum | 1 | 2015 | 1033 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 1048 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 6956 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2013 | 2003 | 0.010 |
Why?
| | Child, Preschool | 1 | 2021 | 11457 | 0.010 |
Why?
| | Lung | 1 | 2017 | 4134 | 0.010 |
Why?
| | Inflammation | 1 | 2015 | 2890 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2560 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2018 | 16273 | 0.010 |
Why?
|
|
Greene's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|